Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm.

Molecular Cancer Therapeutics
Sumanta Kumar PalDavid I Quinn

Abstract

With six agents approved for metastatic renal cell carcinoma (mRCC) within the past 5 years, there has undoubtedly been progress in treating this disease. However, the goal of cure remains elusive, and the agents nearest approval (i.e., axitinib and tivozanib) abide by the same paradigm as existing drugs (i.e., inhibition of VEGF or mTOR signaling). The current review will focus on investigational agents that diverge from this paradigm. Specifically, novel immunotherapeutic strategies will be discussed, including vaccine therapy, cytotoxic T-lymphocyte antigen 4 (CTLA4) blockade, and programmed death-1 (PD-1) inhibition, as well as novel approaches to angiogenesis inhibition, such as abrogation of Ang/Tie-2 signaling. Pharmacologic strategies to block other potentially relevant signaling pathways, such as fibroblast growth factor receptor or MET inhibition, are also in various stages of development. Although VEGF and mTOR inhibition have dramatically improved outcomes for patients with mRCCs, a surge above the current plateau with these agents will likely require exploring new avenues.

References

Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G FyfeA C Louie
Mar 29, 2000·The Journal of Biological Chemistry·A PapapetropoulosW C Sessa
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B I RiniW M Stadler
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Feb 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C M GeorgeW M Stadler
Aug 15, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EscudierA Laplanche
Sep 27, 2003·Blood·Richard LeBlancNikhil C Munshi
Oct 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Micaela HernbergHeikki joensuu
Jan 30, 2004·Recent Progress in Hormone Research·Kevin G PetersSabita Sankar
Nov 1, 2006·Cancer·Toni K ChoueiriRonald M Bukowski
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Apr 26, 2007·Cancer Biology & Therapy·Edwin M PosadasWalter M Stadler
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Jul 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neelima DenduluriSandra M Swain
Jul 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henri RochéHervé Curé
Nov 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Scot EbbinghausRobert Figlin
Apr 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Debashis SarkerJohann S de Bono
May 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eva S Thomas
May 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alain RavaudIman El-Hariry
Jun 6, 2008·American Journal of Clinical Oncology·Robert J AmatoMuhammad Khan
Oct 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Archana Bommi-ReddyDorre A Grueneberg
Feb 10, 2009·Cancer Immunology, Immunotherapy : CII·Jeffrey Weber
May 13, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carolyn D SeibBrent T Shoji
May 22, 2009·International Journal of Urology : Official Journal of the Japanese Urological Association·Norihito SogaYoshiki Sugimura
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Jun 24, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstLee S Rosen
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniJanice P Dutcher
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Loren K MellRalph R Weichselbaum
Jan 14, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael S GordonLia Gore
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cora N SternbergRobert E Hawkins
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierVesna Sneller
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small

❮ Previous
Next ❯

Citations

Oct 26, 2012·AJR. American Journal of Roentgenology·Atul B ShinagareNikhil H Ramaiya
Aug 5, 2015·International Journal of Cancer. Journal International Du Cancer·Nengwang YuBaocheng Wang
Oct 16, 2012·Clinical Genitourinary Cancer·Nicholas J VogelzangThomas E Hutson
Nov 21, 2015·Urologic Oncology·Sumanta K PalDaniel Y C Heng
Apr 3, 2013·Nature Reviews. Urology·Hiromi I Wettersten, Robert H Weiss
Dec 7, 2013·Expert Review of Clinical Pharmacology·Tanya B DorffDavid I Quinn
Jun 28, 2014·The Oncologist·Sumanta K Pal, Naomi B Haas
Feb 27, 2017·Cellular and Molecular Life Sciences : CMLS·Yanjie ZhangX F Steven Zheng
Jul 15, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sumanta K PalPaul Frankel
Dec 21, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T H HoJ E Eckel-Passow

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.